This hypothesis is supported by the evidence that CDX2 silencing interferes with the capacity of 5-ASA, a β-catenin inhibitor with anti-CRC chemoprevention activity, to upregulate MUCDHL expression. Here, CDX2 is linked to colorectal carcinoma.